Six years of qualification
Audited Supplier
In This Store
Category:Excipients > Other Excipients
Product Name:Conbercept Ophthalmic Injection
CAS No.:/
Standard:In-house Standards
Price(USD):0.00
Company:Shenzhen Mellowhope Pharm Industrial Co., Ltd.
Grade: Pharmaceutical Grade
Factory Location: Shen zheng Guangdong China
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: CIF
indicated for the treatment of wet age-related macular degeneration (wet AMD) that functions by blocking VEGF-family proteins. Highlights: 1, Patent-granted countries : US, EU, Japan, Russia, Canada, South Korea, India, Austria and China 2, More completed target, higher efficacy, more outstanding vision improvement, lower administration frequency than Ranibizumab; 3, Recorded by WHO in the 67th list of Recommended INNs; 4, Time to market: 2013 5, Global sales of originator Lucentis: 3700 million US Dollars in 2012; 6, International competitor: Lucentis Ranibizumab® by Genentech (Roche). Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094
Follow Us：
Pharma Sources Insight January 2025
